glp 1 liver fibrosis Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Fatty Disease The Emerging Role of Glucagon-Like
Description
Limited Alternatives: There are few pharmaceutical options specifically targeting PCOS-related weight gain, making GLP-1 agonists an attractive option for many
CNS Neurosci
5,13 Clinical trials in obesity and non-alcoholic fatty liver disease suggest that multi-strain probiotic formulations can modestly improve anthropometric measures, lipid profiles, and, in some studies, increase GLP-1 concentrations
Additionally, gastrointestinal side effects, such as nausea, vomiting, and diarrhea, are commonly associated with GLP-1 receptor agonists, especially during the initial phase of treatment
Greasy, fried, heavily spiced, and very sweet foods are common triggers for GLP-1 related nausea
